Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 132

Sort by

Sort Order Select

Journal Articles

ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

Blood (2024) 144 (7): 757–770.

https://doi.org/10.1182/blood.2024023849

Published: 2024

Includes: Supplemental data

Journal Articles

Lactate administration improves laboratory parameters in murine models of iron overload

Wei Liu, Yue Wu, Huaiqing Wei, Juan Ma, Wenya Feng, Qiuyuan Yang, Shuping Zhang, Tomas Ganz, Sijin Liu

Blood (2024) 143 (11): 1045–1049.

https://doi.org/10.1182/blood.2023021695

Published: 2024

Includes: Supplemental data

Journal Articles

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Blood (2024) 143 (2): 139–151.

https://doi.org/10.1182/blood.2022018658

Published: 2024

Includes: Supplemental data

Journal Articles

Phase I Clinical Study of PA3-17 Injection in Patients with Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma

Blood (2023) 142 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2023-178484

Published: 2023

Journal Articles

Single-Dose Rituximab Plus Glucocorticoid Versus Cyclophosphamide Plus Glucocorticoid in Patients with Newly Diagnosed Acquired Hemophilia a: A Multicenter, Open-Label, Randomized Clinical Trial

Wei Liu, Rongfu Zhou, Panjing Wang, Hu Zhou, Jie Bai, Xianghua Wang, Yueshen Ma, Zhen Song, Yunfei Chen, Xiaofan Liu, Rongfeng Fu, Ting Sun, Mankai Ju, Xinyue Dai, Huan Dong, Feng Xue, Renchi Yang, Lei Zhang

Blood (2023) 142 (Supplement 1): 2628.

https://doi.org/10.1182/blood-2023-174587

Published: 2023

Journal Articles

A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

Wei Liu, Yunhong Huang, Haiyan Yang, Zhiming Li, Zhen Cai, Zhen Wang, Lihong Liu, Ye Guo, Ligen Liu, Rui Huang, Xu Ye, Lugui Qiu

Blood (2023) 142 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2023-177550

Published: 2023

Journal Articles

CM313, a Novel Anti-CD38 Antibody, As a Potential Treatment for Primary Immune Thrombocytopenia: A Phase II Trial

Yunfei Chen, Xu Yanmei, Xuan Cao, Feng Xue, Ting Sun, Wei Liu, Mankai Ju, Rongfeng Fu, Xiaofan Liu, Xinyue Dai, Huiyuan Li, Renchi Yang, Lei Zhang

Blood (2023) 142 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2023-188664

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 2624.

https://doi.org/10.1182/blood-2023-174698

Published: 2023

Journal Articles

Discovery of Novel, First-in-Class Allosteric Modulators of MALT1 Scaffolding Function with Differentiated Pharmacology for NFκB-Driven Malignancies

Yi Yao, Yingzhi Bi, Huadong Sun, Kevin Ling, Huili Xia, Jun Kuai, Patrick DePaolo, Virginie Lafont, David Diller, Ara Aslanian, Samira Jaeger, Joe Wahle, Wei Liu, Ken Carson, Timothy Reilly, Gerry Harriman, Fang Wang

Blood (2023) 142 (Supplement 1): 52.

https://doi.org/10.1182/blood-2023-172899

Published: 2023

Journal Articles

Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial

Blood (2023) 142 (Supplement 1): 687.

https://doi.org/10.1182/blood-2023-174591

Published: 2023

Journal Articles

Acquired Hemophilia a: A Single-Center Study of 165 Patients

Dandan Yu, Feng Xue, Xiaofan Liu, Yunfei Chen, Rongfeng Fu, Ting Sun, Xinyue Dai, Mankai Ju, Huan Dong, Renchi Yang, Wei Liu, Lei Zhang

Blood (2023) 142 (Supplement 1): 2623.

https://doi.org/10.1182/blood-2023-173407

Published: 2023

Journal Articles

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Yanshan Huang, Yuting Yan, Ying Yu, Li Yuxi, Rui Lv, Tingyu Wang, Wenjie Xiong, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2023-188881

Published: 2023

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li Yuxi, Ying Yu, Yanshan Huang, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Wenjie Xiong, Yuting Yan, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2023-186068

Published: 2023

Journal Articles

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2023-188173

Published: 2023

Journal Articles

Factor XI Deficiency in Chinese Patients: Results from a Nationwide Multicenter Retrospective Study

Xiyan Wang, Feng Xue, Wei Liu, Linging Chen, Lei Zhang, Renchi Yang

Blood (2023) 142 (Supplement 1): 5477.

https://doi.org/10.1182/blood-2023-184688

Published: 2023

Journal Articles

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Ying Yu, Yuting Yan, Jun Wang, Wenjie Xiong, Yao Yao, Yanshan Huang, Rui Lyu, Tingyu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Zhijian Xiao, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2023-188786

Published: 2023

Journal Articles

A Single-Center Study of Patients with Isolated Acquired Clotting Factor Deficiency: Clinical Features, Treatments, and Prognosis

Dandan Yu, Feng Xue, Xiaofan Liu, Yunfei Chen, Rongfeng Fu, Ting Sun, Xinyue Dai, Mankai Ju, Huan Dong, Renchi Yang, Wei Liu, Lei Zhang

Blood (2023) 142 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2023-173431

Published: 2023

Journal Articles

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Blood (2023) 142 (Supplement 1): 6088.

https://doi.org/10.1182/blood-2023-188415

Published: 2023

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

NARROW

ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

Lactate administration improves laboratory parameters in murine models of iron overload

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Phase I Clinical Study of PA3-17 Injection in Patients with Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma

Single-Dose Rituximab Plus Glucocorticoid Versus Cyclophosphamide Plus Glucocorticoid in Patients with Newly Diagnosed Acquired Hemophilia a: A Multicenter, Open-Label, Randomized Clinical Trial

A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

CM313, a Novel Anti-CD38 Antibody, As a Potential Treatment for Primary Immune Thrombocytopenia: A Phase II Trial

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Discovery of Novel, First-in-Class Allosteric Modulators of MALT1 Scaffolding Function with Differentiated Pharmacology for NFκB-Driven Malignancies

Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial

Acquired Hemophilia a: A Single-Center Study of 165 Patients

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Factor XI Deficiency in Chinese Patients: Results from a Nationwide Multicenter Retrospective Study

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

A Single-Center Study of Patients with Isolated Acquired Clotting Factor Deficiency: Clinical Features, Treatments, and Prognosis

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only